Jump to Navigation

Ancure

Ancure (Guidant) and Anuerx (Medtronic) were the first two commercially marketed endovascular devices used for the treatment of Abdominal Aortic Aneurysms. Hersh & Hersh was the first law firm in the country to represent individuals regarding these devices and was the first to successfully resolve these cases.

Although the Ancure device is now off the market, it was previously over promoted for use in patients with aortic aneurysms that were better suited for the traditional open repair surgery. Hersh & Hersh continues to represent those injured by the Ancure device. If you or a loved one has been injured by the Ancure endovascular device, please contact us. for more information.

Related News

Hersh & Hersh Continues to Prosecute Guidant Regarding its Medical Device ANCURE After Guidant Pleads Guilty

Guidant, maker of the Ancure Endograft System, pled guilty to 10 felonies in federal court for hiding evidence of significant problems with its Ancure medical device from the FDA. Although the company knew of problems with over 36% of the 7,632 Ancure devices first sold, it reported only 172 of these to the FDA.

The U.S. attorney charged that Guidant allowed sales and marketing personnel to influence medical decisions, even when this put patient health at risk. This complaint echoes those included in the civil suits that Hersh & Hersh has pursued against the company for years.

Hersh & Hersh's civil suits allege that Guidant gave inadequate warnings and intentionally withheld problems with the Ancure system. The company marketed its product as a "safer" and less-invasive method for fixing abdominal aortic aneurysms. This was untrue.

Abdominal aortic aneurysms are weakened places in the aorta that can, if they burst, cause death in a matter of minutes. These aneurysms have traditionally been successfully repaired through an open surgical procedure. However, after approving the device in 1999, the FDA subsequently received reports of device malfunctions and severe adverse events related to Ancure. These included cases of severe blood vessel damage with the Ancure system.

Finally, the civil suits also allege that Guidant, maker of the Ancure Endograft System, did not warn patients that they would need lifetime monitoring to ensure that their endovascular implants don't move, leak, or cause other adverse effects. This level of monitoring substantially raises the lifetime cost of the procedure, and is not necessary with a traditional open surgical repair.

Guidant's Admission Bolsters Hersh & Hersh's Civil Suits Against Manufacturer

June 13, 2003

Guidant, maker of the Ancure Endograft System, pled guilty yesterday to 10 felonies in federal court for hiding evidence of significant problems with the Ancure product from the FDA. Although the company knew of problems with over 36% of the 7,632 Ancure devices sold, it reported only 172 of these to the government.

The U.S. attorney charged that Guidant allowed sales and marketing personnel to influence medical decisions, even when this put patient health at risk. This complaint echoes those included in the civil suits that Hersh & Hersh filed against the company earlier this year.

Hersh & Hersh's civil suits allege that Guidant gave inadequate warnings and intentionally withheld problems with the Ancure system. The company marketed its product as a "safer" and less-invasive method for fixing abdominal aortic aneurysms. This was untrue.

Abdominal aortic aneurysms are weakened places in the aorta that can, if they burst, cause death in a matter of minutes. These aneurysms have traditionally been successfully repaired through an open surgical procedure. However, after approving the device in 1999, the FDA subsequently received reports of device malfunctions and severe adverse events related to Ancure. These included cases of severe blood vessel damage with the Ancure system.

Finally, the civil suits also allege that Guidant, maker of the Ancure Endograft System, did not warn patients that they would need lifetime monitoring to ensure that their endovascular implants don't move, leak, or cause other adverse effects. This level of monitoring substantially raises the lifetime cost of the procedure, and is not necessary with a traditional open surgical repair.

Related Newspaper Articles: